Tag: Cellestial
-
Cellestial Health Presents at the Venture Summit West, California
18th of June 2026; Mountain View, California, USACellestial Health, an innovative pharmaceutical development company offering a paradigm shift approach to Parkinson’s treatments, announces its selection and participation at the 2025 Venture Summit West, which took place June 16–17, 2025 at the Computer History Museun in Mountain View, Silicon Valley. Hosted by youngStartup Ventures, the summit is recognized as…
-
Company of the Year: Therapeutics Development
Cellestial Health is proud to be named the UK Company of the Year 2026 in the field of Therapeutics Development by Excellence Awards. Entries are judged against a number of criteria including:✦ Innovation✦ Strategic thinking✦ Measurable impact✦ Operational excellence “True business excellence emerges when innovation is combined with clarity, adaptability, and responsible leadership,” says Dr…
-
New Beginnings at the BIA Start-Up Festival
On Thursday 21st of May, a panel including Dr Nat Hastings (CEO of Cellestial Health), Dr Jonathan Kwon (CEO of Infinitopes Precision Immunomics), Dr Stasa Stankovic (Co-founder of OvartiX), and Dr Abigail Martin (CEO of InnuneONE), chaired by Inga Deakin of Molten Ventures, discussed what it takes for a new company to be “fit to…
-
#Killer50: Celebrating Cambridge Cluster
It is our great pleasure at Cellestial Health to be recognised alongside our outstanding peers in the Cambridge ecosystem at the annual #Killer50 2026 event by Business Weekly.We will strive to continue delivering advancements in the treatment of brain disorders for the benefit of patients and the scientific community. With gratitude, always 🙏 About #Killer50:Organised…
-
Insights from the BMCS Spring Symposium on Medicinal Chemistry
On Thursday 23rd April 2026, Medicinal Chemistry adviser of Cellestial Health, Lewis Pennicott, attended and contributed to the discussion at the 37th BMCS Spring Symposium on Medicinal Chemistry, the heart of the med chem community. He reports: Fantastic day at the Fielder Centre for the #HatfieldMedChem symposium. Staying at the forefront of these technical advancements…
-
Cellestial Health Joins ET Capital Portfolio and Secures Strategic Support
27th of April 2026; Cambridge, UK Cellestial Health, a biopharmaceutical company developing a new class of drugs for Parkinson’s which affects over 10 million people in the world, is pleased to have recently joined the portfolio of the Cambridge Venture Index Fund (CVIF) of ET Capital – a fund supporting diversified deep science companies spinning out…
-
One Nucleus Awards Gala
Last Thursday 19th of March brought the UK-wide life sciences ecosystem leaders together for a very special occasion of the #ONAwards26 celebration at No.11 Cavendish Square in London. It was a great honour to have the project between Cellestial and The University of Manchester, supported by a Parkinson’s UK grant, recognised as one of the finalist entries in the “Best Industry and…
-
Best Industry and Not for Profit Collaboration: Finalists
The annual One Nucleus Awards dinner celebrates the excellence of the diverse Life Sciences sector, recognising all parts of the community. One Nucleus believe that it is the interactions and dynamics of the entire ecosystem that lead to successful value and impact creation, the vision that resonates with our team’s. This year, the collaboration between…
-
Back at it again in Boston
This week, Dr Nat Hastings represented innovative research into astrocyte pathology in Parkinson’s at the 14th Alzheimer’s & Parkinson’s Drug Development Summit on behalf of Cellestial Health at Hyatt Regency Boston Harbor. Astrocytic lineage is one of the most populous cell types in the brain, yet the damage Parkinson’s pathology does to it remains underappreciated.…
-
BioSeed 2026: What Matters
On Monday 19th of January, the Cellestial Team attended BioSeed by OBN to re-connect with the London life sciences community and share why our approach to astrocytic network restoration matters in Parkinson’s. ✦ For brain cells, we are looking to reduce the burden of abnormal protein aggregates and inflammation via a novel mechanism✦ For people…